There are now more than 1,039 FDA-authorized AI tools for radiology. At the RSNA annual meeting in 2025, more than 200 AI vendors exhibited on the show floor. That is an extraordinary amount of choice — and an extraordinary amount of noise for radiology leaders trying to make sound, durable procurement decisions.
The fundamental challenge is that FDA clearance, while a necessary baseline, is not sufficient evidence that a tool will perform as advertised in your specific clinical environment. A 2025 systematic review published in JAMA Network Open found that of the 717 radiology AI devices with available submission documentation, only 33 — just 5% — underwent prospective testing. Only 8% included a human-in-the-loop assessment, and only 29% incorporated any clinical testing at all. Ninety-seven percent of all AI medical devices are cleared via the 510(k) pathway, which establishes safety and substantial equivalence to a previously cleared device, but does not require clinical efficacy evidence or multisite validation. A cleared device is legally deployable. That is not the same thing as a clinically useful one.
This post provides a practical evaluation framework — grounded in current evidence and endorsed frameworks from the ACR, ESR, RSNA, and other leading radiology societies — for making confident, well-reasoned AI procurement decisions. It covers the questions to ask, the data to demand, the red flags to recognize, and the implementation conditions that determine whether purchased AI actually delivers value.
The single most common mistake radiology departments make when evaluating AI is starting with the technology rather than the clinical or operational problem they are trying to solve. A tool that produces impressive benchmark results is not useful if it addresses a challenge your department does not have, or if your actual constraint lies in a different part of the workflow entirely.
Before engaging any vendor, radiology leaders should be able to clearly articulate what specific bottleneck, quality gap, or coverage constraint is motivating the evaluation. Is the problem that urgent cases are not being identified and prioritized quickly enough? Is it that a high volume of routine studies is consuming radiologist time that could be better spent on complex cases? Is it report generation speed and consistency? Is it subspecialty depth in specific modalities your team does not have? The answer to that question determines which category of AI tool is relevant — and just as importantly, which categories are not relevant regardless of how well they perform on their stated task.
The ECLAIR guidelines, developed by a consortium of academic and industry radiology AI experts and published in European Radiology, define this as "intended use fit" — one of the foundational evaluation criteria for commercial AI solutions. The guidelines ask: Does the AI solution provide useful information that was not available before? Does it match the specific clinical pathway and patient mix you serve? Is it designed for the function you actually need — double reading, triage, quality control, report generation, or something else? Matching the tool's intended function to your institutional need is the first filter. Everything else is secondary.
Once intended use fit is established, the most important single dimension of AI evaluation is the quality and applicability of clinical validation evidence. This is where most purchasing conversations fail to go deep enough — and where the performance gap between research claims and real-world results most commonly originates.
The generalizability problem in radiology AI is well-documented and serious. A 2024 Nature Medicine study found that when AI models are tested outside of their original training environment, performance can drop by as much as 20 percentage points. Of AI models that reported validation site data in 2024, 38% were tested on data from a single hospital. A pneumonia detection model trained on chest X-rays from one institution performed substantially worse at a different facility. A 2025 article on AI integration from the European Journal of Radiology described this directly: accuracy as a primary performance metric is misleading in the absence of a representative training dataset, because a near-perfect accuracy score may not generalize to a clinical setting that differs even slightly from the algorithm's training source.
The practical implication is straightforward: ask every vendor where their model was trained and where it has been validated. Multisite validation — ideally involving at least three to five institutions with different scanner types, patient demographics, and imaging protocols — is the minimum acceptable evidence standard for a tool being considered for production deployment. Single-site validation, particularly from a large academic medical center, should not be assumed to generalize to community hospital settings, urgent care environments, or regional imaging centers with different patient populations.
The FDA's January 2025 draft guidance on AI lifecycle management specifically addresses this issue, recommending that vendors implement post-market performance monitoring and drift detection — mechanisms to identify when a deployed model's real-world performance is deteriorating relative to its validated baseline. When evaluating vendors, ask specifically whether they provide post-deployment performance monitoring as part of their service contract, and what their process is for alerting customers when performance metrics fall below defined thresholds.
The ACR-RSNA multi-society statement on developing, purchasing, implementing, and monitoring AI tools identifies prospective testing as the highest-quality evidence standard for clinical AI. Retrospective testing on historical data is a starting point, but it cannot account for the operational realities of live clinical workflow — including the effect of alert fatigue, the behavior of radiologists when AI outputs are present, and the performance of the tool on scanner models or acquisition protocols not represented in the training data. Ask vendors whether their validation studies were prospective or retrospective, whether a radiologist was in the loop during testing, and whether study design included subgroup analysis by patient demographics, scanner type, and clinical setting.
The European Radiology review of 173 commercially available AI products published in 2025 found that products with any peer-reviewed evidence increased from 36% in 2020 to 66% by 2023 — progress, but still meaning that more than one third of commercially available products at that time had no published peer-reviewed evidence at all. Requiring peer-reviewed validation studies, ideally vendor-independent ones, as a condition of proceeding past initial vendor conversations is a reasonable standard. A vendor that cannot provide published or preprint evidence of their tool's performance should be asked directly why not, and their answer should weigh heavily in the evaluation.
Sensitivity and specificity figures in vendor materials are typically reported under idealized conditions. The false positive rate matters as much as sensitivity — and in high-volume settings, it matters more for day-to-day operations. An AI triage tool with 90% sensitivity and 95% specificity sounds strong. At a practice processing 500 CT scans per day, 5% specificity loss generates 25 additional false-positive cases daily that require radiologist review time to resolve. That aggregate burden can offset, or in some practice settings reverse, the efficiency gains the tool was purchased to provide. A national teleradiology program study found that false positives from a deep learning intracranial hemorrhage tool added 74 seconds per flagged study — aggregating to more than 82 hours of lost radiologist efficiency across the program's volume.
Ask vendors for positive predictive value (PPV) and negative predictive value (NPV) data from real-world deployments, not just sensitivity and specificity from validation studies. These metrics are more directly actionable for operational planning, because they tell you what fraction of the AI's alerts will actually require clinical action — and therefore what the true workflow burden of the tool will be at your specific practice volume.
A tool that performs well in isolation but integrates poorly into your existing workflow will not deliver its performance benefits in practice. Integration quality is one of the most underweighted factors in AI procurement and one of the most frequently cited causes of implementation failure.
A 2024 Radiology paper on AI integration standards identified the key challenge directly: radiology AI touch points exist throughout the imaging chain — study ordering, preprocessing, image acquisition, postprocessing, reporting, and storage — and accommodating custom integrations at each of these points creates substantial operational and maintenance burden. Variable adoption of standards, multiple AI result formats, and an increasing number of concurrent tools contribute to integration complexity that scales poorly as a practice's AI portfolio grows.
The standards-based interoperability framework that minimizes this complexity relies on DICOM compliance for image data exchange, HL7 FHIR for clinical data integration, and conformance with RSNA and Integrating the Healthcare Enterprise (IHE) profiles for how AI outputs are communicated back to radiologists in their reading workflow. When evaluating vendors, ask specifically how their tool delivers its outputs — does it return structured DICOM annotations visible in your current PACS viewer, or does it require a separate viewer or dashboard? Requiring radiologists to toggle between their standard PACS and a separate AI interface is a workflow friction point that reduces adoption even among radiologists who are motivated to use the tool.
Cloud-based solutions have become the dominant deployment model for radiology AI, and for good reason: they enable deployment without large upfront hardware investments, facilitate continuous updates, and support multi-site integration. But cloud deployment raises data security and compliance questions that must be explicitly addressed before any tool with patient imaging data goes live. Verify that the vendor's platform is HIPAA-compliant, that PHI (protected health information) is appropriately de-identified or secured in transit and at rest, that data access controls and audit trails meet your institution's governance standards, and that the vendor's subprocessor agreements are reviewed and approved by your IT security and compliance teams.
A core concern among radiologists evaluating AI tools is the "black box" problem — the tendency of deep learning models to produce outputs without any interpretable explanation of how they arrived at them. In a 2025 Philips Future Health Index survey, 63% of radiologists expressed concerns about bias in AI algorithms, and an equal proportion worried about legal liability when using AI in clinical decisions. These concerns are directly related to transparency: when radiologists cannot understand why an AI flagged or did not flag a finding, it is difficult to decide how much weight to give the output, and impossible to identify the conditions under which the tool is systematically wrong.
Modern AI tools increasingly include explainability features — saliency maps, attention heatmaps, confidence scores, or case-based reasoning displays — that indicate which regions of the image most influenced the model's output. These features have real value for building radiologist trust and for identifying when AI behavior appears inconsistent with clinical expectations. However, the ACR-RSNA multi-society statement includes an important caveat: explainability features can be useful, but radiologists sometimes find them less helpful than promised, and they should not be treated as a substitute for understanding the tool's validated performance characteristics and limitations. A saliency map that highlights the right region for the wrong reasons, or that provides false confidence in an incorrect output, creates a different kind of risk than a transparent display of uncertainty.
The practical minimum standard is that every AI tool should be able to provide: a clear statement of what its output represents (a probability score, a binary flag, a segmentation, a draft report), the performance characteristics of that output (sensitivity, specificity, PPV, NPV in relevant clinical populations), the populations and protocols on which it was validated, and the known limitations and failure modes. Any vendor who cannot or will not provide clear answers to these questions before procurement should be a red flag.
FDA clearance is a necessary condition for clinical deployment of AI tools in the United States, but as the JAMA Network Open systematic review makes clear, the 510(k) pathway that the vast majority of AI devices use establishes substantial equivalence to a predicate device, not clinical efficacy. Understanding what a vendor's regulatory status actually means — and does not mean — is an important part of due diligence.
The FDA's December 2024 final guidance on Predetermined Change Control Plans (PCCPs) and its January 2025 draft guidance on AI lifecycle management both signal a regulatory evolution toward requiring continuous post-market performance monitoring for AI devices that update their algorithms over time. Ask vendors whether they have a PCCP in place — a documented plan describing how their model can be updated without requiring a new 510(k) submission — and what their process is for notifying customers of algorithm updates, performance changes, or identified safety signals. Version control matters: an algorithm update that changes performance characteristics should trigger re-evaluation by your department, and vendor contracts should specify notification requirements and rollback procedures.
The EU AI Act, finalized in 2024, takes a more stringent approach and is already shaping vendor practices globally: it classifies radiology AI as high-risk and mandates clinical validation, conformity assessments, and post-market monitoring with traceability of training datasets. For healthcare systems evaluating tools from vendors with global regulatory exposure, understanding how a tool's EU compliance posture compares to its FDA clearance documentation can provide additional insight into the rigor of its validation program.
Radiology AI procurement decisions are often evaluated primarily on upfront cost, but the total cost of ownership includes several categories that are rarely prominent in vendor proposals and frequently underestimated in budget planning.
Integration cost is typically the largest hidden cost. Custom integrations between AI platforms and existing PACS, RIS, and EHR systems require IT resources for implementation, testing, and ongoing maintenance. If the vendor does not use standards-based interoperability, integration costs can be substantial and recurring. Training cost is the second major underestimated expense. Radiologists who are not trained in a tool's limitations, performance characteristics, and appropriate use cases are unlikely to use it well — and may use it in ways that create liability risk. This training requirement is not a one-time event; it requires ongoing education as the tool evolves, as new radiologists join the practice, and as the tool is deployed in new clinical contexts.
Governance cost — the ongoing operational overhead of running an AI oversight committee, monitoring tool performance post-deployment, reviewing cases where AI and radiologist conclusions diverged, and managing vendor relationships — is the third frequently underestimated category. The ACR-RSNA multi-society statement is explicit that continuous evaluation and quality control of AI tools is a critical aspect of clinical implementation and is currently a weakness for most AI deployments. Building that governance infrastructure takes time, requires designated personnel, and should be factored into the total cost calculation before any procurement decision is finalized.
The most reliable protection against expensive, disruptive implementation failures is a structured pilot before broad deployment. Imaging leaders who have evaluated AI at scale consistently recommend a 60 to 90 day pilot in a single high-impact service line — emergency stroke CT, mammography triage, or chest radiograph reporting are the most common starting points — with pre-defined baseline metrics, clear success criteria, and a governance structure in place before the pilot begins.
Baseline metrics should include median turnaround time for the target study type, positive predictive value of AI alerts in your specific patient population, recall rate, radiologist discrepancy rate, and if measurable, patient outcome data for the targeted condition. These baselines allow a genuine comparison between pre- and post-AI performance rather than relying on vendor-supplied performance figures from different clinical environments. Success criteria should be defined before the pilot begins, not after, so that the evaluation is not subject to post-hoc rationalization of marginal results.
The pilot period should also include a structured feedback mechanism for radiologists using the tool. The Philips 2025 Future Health Index found that 41% of radiologists reported AI tools deployed at their institution did not adequately address their real-world workflow needs — a finding that reflects, in part, the consequence of deploying without adequate radiologist input into the evaluation process. Radiologists who are asked to evaluate a tool, who can articulate what is and is not working about it, and whose feedback shapes the deployment configuration are significantly more likely to adopt it effectively than those who have it imposed on their workflow.
Every dimension of AI evaluation described above shares a common premise: AI tools in radiology are decision-support instruments for skilled radiologists, not autonomous diagnostic systems. The performance of every AI tool currently deployed in clinical settings depends on expert human oversight. As a 2025 review in Radiology: Artificial Intelligence put it directly, AI methods where model predictions are not repeatable, do not generalize within the scope of their development, or are not well-calibrated should not be implemented — and the determination of whether those conditions are met requires clinical expertise that no algorithm can provide for itself.
This is the context in which Transparent Imaging approaches AI: as a technology layer that augments the work of a skilled, subspecialty-anchored radiology team — not as a substitute for the team itself. Founded in 2019 by David Zelman, D.O. (PET and Body Imaging) and Eric Ledermann, D.O., M.B.A. (MSK Radiology), Transparent Imaging was built around the insight that access to peer-reviewed, subspecialty reads is the foundational requirement for quality radiology — and that AI tools add the most value when they operate on top of that foundation, not instead of it. With 100+ radiologists across subspecialties delivering peer-reviewed reads and subspecialty consultation support, the practice provides imaging centers and health systems with the human infrastructure that makes AI investment meaningful rather than a substitute for expertise they do not have.
For radiology departments evaluating AI technology, the most important question is not which tool has the most impressive benchmark performance. It is which tool, in combination with a skilled and well-governed radiology team, will produce the most reliable improvement in diagnostic quality and operational efficiency for your specific patient population and clinical environment. That question requires both rigorous AI evaluation and an honest assessment of the human capability foundation on which any AI investment depends.
Based on the evaluation criteria covered in this post and endorsed by leading radiology societies, the following checklist captures the key questions to bring to any radiology AI vendor evaluation.
On clinical validation: Has the tool been validated prospectively, or only retrospectively? How many institutions and scanner types were included in validation? What is the demographic diversity of the validation dataset? Are there published, peer-reviewed, vendor-independent studies? What are the sensitivity, specificity, PPV, and NPV in populations comparable to yours?
On generalizability: Has the tool been deployed outside the institution where it was developed? What performance variation was observed across deployment sites? What is the vendor's process for identifying and communicating performance drift after deployment?
On integration: Is the tool DICOM-compliant and does it return results to your existing PACS viewer, or does it require a separate interface? What is the estimated integration timeline and cost? What standards and protocols does the vendor use for PACS, RIS, and EHR connectivity?
On transparency: Does the tool provide confidence scores or explainability outputs? Can the vendor clearly articulate the known failure modes and limitations of the tool? What are the data security, HIPAA compliance, and PHI handling protocols?
On regulatory and governance: What is the FDA clearance pathway and what specifically was cleared? Does the vendor have a Predetermined Change Control Plan? How are algorithm updates communicated and versioned? What post-market surveillance does the vendor conduct and report?
On cost and support: What is the total cost of ownership including integration, training, and governance overhead? What does the vendor's ongoing support and performance monitoring service include? What are the contract terms for performance guarantees, SLAs, and exit provisions?
FDA clearance is a necessary baseline but not sufficient evidence of clinical effectiveness in your specific environment. A 2025 JAMA Network Open systematic review of 717 radiology AI devices with available submission documentation found that only 5% underwent prospective testing, only 8% included a human-in-the-loop assessment, and only 29% incorporated any clinical testing at all. The 510(k) pathway — used for 97% of AI medical devices — establishes substantial equivalence to a predicate device, not clinical efficacy. A cleared device is legally deployable; that is not the same as a clinically useful or appropriately validated one. FDA clearance should be treated as the floor of your evaluation requirements, not the ceiling. The additional questions about multisite validation, prospective testing, false positive rates in your specific patient population, and PACS integration quality are what determine whether a tool will actually perform as expected in your department.
The evidence strongly supports requiring validation across at least three to five institutions with meaningfully different patient demographics, scanner types, and imaging protocols before treating performance figures as applicable to your clinical environment. A 2024 Nature Medicine study found performance drops of up to 20 percentage points when AI models were deployed outside their training environment. Of AI models that reported validation site data in 2024, 38% were validated on data from a single hospital — a number that makes those models' published performance figures unreliable predictors of real-world performance in different settings. If the only validation data a vendor can provide comes from a single academic medical center, and your practice is a community hospital or regional imaging center with a different patient mix and imaging infrastructure, you should treat that validation evidence with significant caution and require a structured pilot in your own environment before committing to full deployment.
The most common and costly integration mistake is deploying AI tools that require radiologists to work outside their primary PACS environment — toggling to a separate dashboard or interface to see AI results. This friction point directly undermines adoption, because even radiologists who are motivated to use an AI tool will deprioritize alerts that require additional steps to access. The best-integrated AI tools return structured, actionable results directly into the radiologist's standard PACS workflow, using DICOM-compliant structured reports or annotations that appear natively in the reading environment. A related mistake is underestimating the IT resource requirements for custom integrations. Standards-based tools that use established DICOM and HL7 FHIR protocols minimize custom integration work and reduce the ongoing maintenance burden as PACS systems and AI algorithms evolve. When evaluating vendors, asking specifically where and how their outputs appear in a radiologist's standard workflow — and requesting a live demonstration in your actual PACS environment rather than a vendor-controlled demo — reveals integration quality far more reliably than written specifications.
Post-deployment performance monitoring is where most radiology AI governance programs are currently weakest — a gap the ACR-RSNA multi-society statement explicitly identifies as a critical concern. A practical monitoring program should include three components. First, ongoing tracking of the tool's operational performance metrics — alert volume, PPV of alerts in your patient population, radiologist response rate to alerts, and turnaround time changes — compared against the baselines established before deployment. Second, regular case review of disagreements between AI alerts and radiologist conclusions, using these divergences as quality signals: when AI flags something a radiologist does not confirm, was the AI right or wrong? Third, version management: algorithm updates should be logged, change notifications from vendors should be reviewed, and significant updates should trigger a reassessment of performance baselines rather than being silently absorbed into production. Establishing a biweekly or monthly AI oversight committee — including the radiology department lead, a quality assurance representative, and IT — provides the governance structure to make these monitoring activities systematic rather than ad hoc.
Productivity gain claims should always be interrogated for the conditions under which they were measured. Ask specifically: Was the study prospective or retrospective? Were the radiologists in the study representative of your team in terms of experience level and volume? What was the baseline productivity of the comparison group? Were gains measured on all study types the tool is marketed for, or only a specific subset? And critically: what happened to accuracy in the studies where productivity improved? The most credible productivity evidence comes from peer-reviewed publications with vendor-independent authors, measured in real clinical workflows across multiple sites, with accuracy measured alongside efficiency. The Northwestern Medicine study published in JAMA Network Open in June 2025 — which showed 15.5% documentation time reduction across nearly 24,000 real-world radiographs with no measured accuracy loss — is a strong example of the evidence standard to look for. Claims of productivity improvement without accompanying accuracy data, or based solely on single-site studies in controlled research environments, should be viewed as hypothesis-generating rather than deployment-justifying.